HomeAstellas Pharma Inc.

Trade Astellas Pharma Inc. - 4503 CFD

Market is not available at the momentMarket information is presented
as of 2026-11-16T06:06:05+00:00
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread5.6
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
¥1,000
Overnight funding adjustment
Charges from full value of position
-0.01444 %
(-¥1)

Trade size with leverage ~ ¥10,000

Money from leverage ~ $¥9,000


-0.01444%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
¥1,000
Overnight funding adjustment
Charges from full value of position
-0.00778 %
(-¥1)

Trade size with leverage ~ ¥10,000

Money from leverage ~ $¥9,000


-0.00778%
Overnight funding adjustment time22:00 (UTC)
CurrencyJPY
Min traded quantity1
Margin10.00%
Stock exchangeJapan
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close2696.4
Open2717.47
1-Year Change44.6%
Day's Range2715.38 - 2758.83

Trade Astellas Pharma Inc. - 4503

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. It offers XTANDI, an androgen receptor signaling inhibitor for the treatment of prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of overactive bladder (OAB); and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ transplant rejection. The company also provides Vesicare for OAB treatment; Eligard for prostate cancer treatment; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical collaboration agreement with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and Cytokinetics, Incorporated, as well as an agreement with BANDAI NAMCO Entertainment Inc. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready